Title
Category
Credits
Event date
Cost
COPD in 2025: Early Detection, Diagnostic Precision, and Emerging Therapies
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
This session explores the latest updates in the diagnosis and management of chronic obstructive pulmonary disease (COPD) as outlined in the 2025 GOLD Report. Early case finding, refined spirometry protocols and novel therapeutic options are discussed, along with the importance of pre-bronchodilator spirometry, strategies for early detection in at-risk populations, and the integration of new treatments into updated treatment algorithms.
Gene Therapy in the Genomic Era: Promise, Progress and Patient Impact
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
Gene therapy technologies are revolutionizing treatment for genetic diseases. This session explores the science, clinical applications, and patient perspectives, with a focus on sickle cell disease and emerging technologies like CRISPR.
Facing Dementia: Early Diagnosis, Communication and Compassionate Care
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 ASWB - Social Workers
$0.00
Dementia care poses growing challenges in health care, requiring early recognition, accurate diagnosis, and compassionate, evidence-based care. This activity clarifies distinctions between dementia and mild cognitive impairment, reviews common subtypes, and highlights core strategies for improving care delivery and enhancing support for patients and caregivers.
Fatty Liver Disease: The Silent Epidemic
  • Disease management
  • Transplantation
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
This presentation reviews the latest evidence-based strategies for identifying, diagnosing and managing non-alcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD). The progressive form of this disease, non-alcoholic steatohepatitis (NASH), is on track to become the leading cause of liver transplantation in the United States. Learn about current guidelines, risk-stratification tools, and emerging therapies, and gain insights to improve early detection and optimize patient outcomes.

Pages